Krystal Biotech GAAP EPS of $2.05 beats by $0.28, revenue of $1.1B beats by $973.46M
Krystal Biotech (KRYS) reported Q3 GAAP EPS of $2.05, exceeding estimates by $0.28. Revenue reached $1.1B, a 1024.7% year-over-year increase, surpassing expectations by $973.46M. The company had $1.2B in cash and investments as of September 30, 2026, with product revenue at $127.3M.
How this was made
The 30-second read
Why it matters
The earnings surprise is likely to trigger a short-term rally in KRYS, with potential spillover to the biotech sector.
Market read
The earnings beat provides a clear catalyst for KRYS and may influence sentiment in the broader biotech space.
What to watch
Guidance for future quarters was not disclosed, leaving forward outlook uncertain.
Background
Krystal Biotech released its Q3 earnings, reporting a significant beat in both EPS and revenue.
Ticker impact
Q3 GAAP EPS of $2.05 beats expectations by $0.28 and revenue of $1.1B beats by $973.46M, a material earnings surprise.
upward pressure as the market prices in the earnings beat
Both EPS and revenue significantly exceeded expectations, indicating better-than-forecast performance and prompting buying interest.
Market effects
Biotech sector may see broader uplift as a peer demonstrates strong earnings.
US biotech stocks could benefit from the surprise.
Limited to investors focused on US-listed biotech equities.
Counterpoint
Some investors may view the beat as unsustainable if driven by one-time items.
Key entities
- CompanyKrystal Biotech
US-listed biotech firm reporting Q3 earnings.
